Evaluation The Clinical Potential of Interleukin Inhibitors in the Treatment of Psoriasis and Psoriatic Arthritis Evaluation HMP Education would appreciate your feedback on the quality and impact of this activity.Please answer the following questions, some of which include a 5-point Likert scale (5 = strongly agree/excellent/great deal; 1 = strongly disagree/poor/very little). To what extent are you able to better achieve each of the following learning objectives? Outline the role of the IL-23/Th17 and Th1 pathways in the pathogenesis of PsO and PsA and its implications for treatment 5 4 3 2 1 Evaluate key efficacy and safety data for approved IL inhibitors for the treatment of PsO and PsA 5 4 3 2 1 Describe the clinical rationale and considerations for IL inhibitors for the treatment of PsO and PsA 5 4 3 2 1 Integrate IL inhibitors into collaborative treatment strategies for patients with PsO and PsA, where appropriate 5 4 3 2 1 Please rate the faculty on the following: Joseph Merola, MD: Knowledge, expertise, and teaching ability 5 4 3 2 1 Please rate the following components relating to this activity: Content 5 4 3 2 1 Relevance to your practice 5 4 3 2 1 Educational format 5 4 3 2 1 Audience-participation portions (eg., Q&A, polling, pre/post-testing) 5 4 3 2 1 Resources and/or other materials supporting the activity 5 4 3 2 1 Overall 5 4 3 2 1 Therapeutic recommendations presented in this activity did not encourage inappropriate or excessive use of products/devices. Agree Disagree How many patients with Psoriasis and Psoriatic Arthritis do you see during a typical week? 0 patients 1-10 patients 11-20 patients 21-30 patients More than 30 patients Do you feel like there were any new data presented? Yes, please specify: No Did you learn anything new? Yes, please specify: No Did you gain confidence on the new information? Yes, why? No, why? Did this program include opportunities to learn as a part of a healthcare team? Yes, please specify: No Which of the following cytokines promotes immune cell differentiation, induction of a Th17 immune response, and the production of inflammatory cytokines involved in psoriasis and psoriatic arthritis pathogenesis? TNF-a IL-17 IL-21 IL-23 In the Phase 2b FRONTIER 1 clinical trial , a greater proportion of patients with moderate to severe psoriasis who received which of the following achieved PASI 75 (primary endpoint) as well as PASI 90 and PASI 100 compared to placebo at week 16? Guselkumab JNJ-2113 Tildrakizumab Ustekinumab Which of the following demonstrated significant and durable improvements in symptoms of psoriatic arthritis in patients with PsA who were intolerant to prior TNF-a therapy? Guselkumab Ixekizumab Risankizumab Ustekinumab How confident are you in your ability to appropriately utilize IL inhibitors in management strategies for psoriasis and psoriatic arthritis? Very confident Confident Somewhat confident Not very confident Not at all confident Do you intend to make any additional changes to your practice as a result of information gained from this activity? Please be specific. Yes, please describe: No What challenges or barriers outside of your control may prevent you from changing your practice? Adverse effects of available treatments Affordability/cost Institutional policy Insurance/formulary Lack of patient education/engagement Limited resources/time Need more information on optimal management strategies Outdated or unclear guidelines Patient adherence Other: How might future activities help you address those barriers? 255 characters max The information presented in this activity did not serve to advance a proprietary interest of any commercial entity. Agree Disagree Based on my participation in this activity, I anticipate I will more often: (select all that apply) Evaluate patient characteristics and preferences when considering PsO and PsA treatment Initiate treatment as early as possible for PsO and PsA Implement a treat-to-target approach to PsO and PsA management Implement strategies to mitigate AEs associated with PsO and PsA treatment Utilize IL inhibitors for the treatment of PsO and PsA in clinical practice, where appropriate Remain apprised of the clinical data associated with newer and emerging IL inhibitors for the treatment of PsO and PsA Other (please specify): Previous